Eliem Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 1.7 million compared to USD 22.29 million a year ago. Basic loss per share from continuing operations was USD 0.06 compared to USD 0.84 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.88 USD | +4.72% | +15.18% | +228.89% |
05-15 | Eliem Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-11 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
1st Jan change | Capi. | |
---|---|---|
+228.89% | 258M | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+3.23% | 22.78B | |
-10.44% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- ELYM Stock
- News Eliem Therapeutics, Inc.
- Eliem Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024